Journal: International Journal of Molecular Sciences

Article Title: GPR41 Regulates the Proliferation of BRECs via the PIK3-AKT-mTOR Pathway

doi: 10.3390/ijms24044203

Figure Lengend Snippet: GPR41KD inhibits the expression of key proteins of the PIK3-AKT-mTOR pathway ( n = 3). ( A , B ) GPR41KD inhibited the expression of PIK3, AKT, S6K1, mTOR. ( C , D ) GPR41KD inhibited the expression of p-mTOR, p-S6K1, p-4EBP1. GAPDH serve as the loading controls for normalization. The data are expressed as the mean ± SEM and analyzed by t -test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.

Article Snippet: The following main antibodies were obtained from Cell Signaling Technology (CST, Shanghai, China): GAPDH, PIK3, AKT, p-AKT, mTOR, p-mTOR, S6K1, p-S6K1, 4EBP1 and p-4EBP1 (1:1000; CST).

Techniques: Expressing

Journal: International Journal of Molecular Sciences

Article Title: GPR41 Regulates the Proliferation of BRECs via the PIK3-AKT-mTOR Pathway

doi: 10.3390/ijms24044203

Figure Lengend Snippet: Primers for real-time PCR analyses.

Article Snippet: The following main antibodies were obtained from Cell Signaling Technology (CST, Shanghai, China): GAPDH, PIK3, AKT, p-AKT, mTOR, p-mTOR, S6K1, p-S6K1, 4EBP1 and p-4EBP1 (1:1000; CST).

Techniques: Real-time Polymerase Chain Reaction, Sequencing

Journal: Frontiers in Pharmacology

Article Title: Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy

doi: 10.3389/fphar.2023.1112123

Figure Lengend Snippet: Vericiguat restored AKT/mTOR and FoxO1 pathways in DOX mice. (A) Expression of p-AKT, AKT, p-mTOR, mTOR, p-p70S6K, p70S6K, p-4EBP1, 4EBP1, p-FoxO1 and FoxO1 detected through western blot. (B–F) Relative protein expression levels of p-AKT, AKT, p-mTOR, mTOR, p-p70S6K, p70S6K, p-4EBP1, 4EBP1, p-FoxO1 and FoxO1. n = 5; *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The membranes were blocked in 5% non-fat dried milk/Tween 20-tris buffered saline (TBST) for 1 h and incubated overnight at 4°C with primary antibodies: Anti-Fbx32 (Abcam ab168372), Anti-MuRF1 (Proteintech 55456-1-AP), Anti-Gapdh (Proteintech 66004-1-I), Anti-GUCY1A3 (Proteintech 12605-1-AP), Anti-GUCY1B3 (Abcam ab154841), Anti-AKT (CST 4685S), Anti-p-AKT (CST 4060S), Anti-mTOR (Proteintech 66888-1-IG), Anti-p-mTOR (CST D9C2), Anti-p70S6K (CST E8K6T), Anti-p-p70S6K (CST D5U1O), Anti-4EBP1 (CST 53H11), Anti-p-4EBP1 (CST 236B4).

Techniques: Expressing, Western Blot

Journal: Breast Cancer : Targets and Therapy

Article Title: Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins

doi: 10.2147/BCTT.S390017

Figure Lengend Snippet: Western blot analysis of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathways in the MDA-MB-468 cell line treated with gefitinib and everolimus and their relative expression. ( A ) Western blotting of the expression patterns of the EGFR and mTOR pathway proteins after treatment with gefitinib and everolimus alone and in combination ( P < 0.05). ( B – I ) Expression of EGFR, phosphorylated EGFR, mTOR, phosphorylated mTOR, ribosomal protein S6 kinase (S6K1), phosphorylated S6K1, 4E binding protein 1 (4EBP1), and phosphorylated 4EBP1 proteins after intervention with gefitinib and everolimus alone and in combination ( P < 0.05).

Article Snippet: Primary rabbit mAb to mTOR (2972), p-mTOR (Ser2448) (2971), 4EBP1 (9452), p-4EBP1 (Thr37/46) (2855), p-70S6 Kinase (9202), p-70S6 Kinase (9205), EGFR (2232), and p-EGFR (D7A5) XP ® (3777) were purchased from Cell Signaling (USA).

Techniques: Western Blot, Expressing, Binding Assay